Alnylam Pharmaceuticals, Inc. Common Stock Earnings Dividend

Alnylam Pharmaceuticals, Inc. Common Stock’s revenue jumped 66.86% since last year same period to $1290.95Mn in the Q2 2026. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. Common Stock has generated 10.6% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc. Common Stock’s net profit jumped 348.19% since last year same period to $164.49Mn in the Q2 2026. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. Common Stock has generated -20.15% fall in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 248.75% since last year same period to 12.74% in the Q2 2026. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. Common Stock has generated -27.8% fall in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.44 - a -2.04% fall from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.44.

Alnylam Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 278.12% since last year same period to 1.21 in the Q2 2026. This indicates that the Alnylam Pharmaceuticals, Inc. Common Stock has generated 278.12% annual rate of jump in its earning per share (EPS) in the last 4 quarters.